Once daily multiple sclerosis treatment approved for use in Scotland
The Scottish Medicines Consortium has approved Zeposia® (ozanimod) for use in relapsing remitting multiple sclerosis patients.
List view / Grid view
News
Erleada drug combination extends progression-free survival in prostate cancer trial
In the Phase III ACIS study, prostate cancer patients treated with a combination of Erleada® and Zytiga® plus prednisone were less likely to die than participants receiving Zytiga and prednisone.
Trial to assess AstraZeneca’s long-acting COVID-19 antibody therapy
The ACTIV-3 sub-study will evaluate the safety and efficacy of the AZD7442 synthetic antibody combination in at least 150 participants with mild-to-moderate COVID-19.
Peginterferon-lambda accelerates COVID-19 recovery, finds trial
Peginterferon-lambda rapidly reduced non-hospitalised COVID-19 patients’ viral loads and expedited their recovery in a Phase II study.
FDA approves third gene therapy for large B-cell lymphoma
Breyanzi (lisocabtagene maraleucel) was approved on the 54 percent complete remission rate achieved in diffuse large B-cell lymphoma trials.
Chinese police seize over 3,000 fake COVID-19 vaccines
Pharmaceutical counterfeiting brought to the fore, as more than 3,000 saline filled vials being sold as COVID-19 vaccines were seized in Chinese police raids.
Africa to receive first COVID-19 vaccine doses in February
COVAX has allocated 90 million doses of AstraZeneca’s COVID-19 vaccine and 320,000 doses of the Pfizer-BioNTech vaccine to African countries.
![Jazz Pharmaceuticals Sign with Logo [Credit: Michael Vi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Jazz-pharmaceuticals-300x278.jpg)
![Jazz Pharmaceuticals Sign with Logo [Credit: Michael Vi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Jazz-pharmaceuticals-e1612534960797.jpg)
Jazz to acquire GW Pharmaceuticals for $7.2 billion
According to Jazz Pharmaceuticals, the combined company will be a leader in neuroscience, well positioned to maximise the value of its diversified portfolio.
Novel HIV vaccine approach shows promise in “landmark” first-in-human trial
The vaccine was able to target the desired immune cells and could become the first stage of a multi-step vaccine strategy to combat HIV and various other viral diseases.
NICE recommends treatment for non-squamous, non-small cell lung cancer
Pembrolizumab with pemetrexed and platinum chemotherapy has been recommended by NICE to treat non-squamous, non-small cell lung cancer.
J&J submits COVID-19 vaccine data to FDA for emergency authorisation
J&J have submitted Phase III trial data in their application to the FDA for emergency authorisation of their COVID-19 vaccine candidate.
EMA begins rolling review of Novavax’s NVX-CoV2373 COVID-19 vaccine
The review will evaluate data from preclinical and clinical studies of NVX-CoV2373 to expedite the vaccine’s marketing authorisation approval later.
Investigational COVID-19 vaccine tablet safely induces immune response in Phase I
A preliminary analysis shows VXA-CoV2-1 was well-tolerated and induced T-cell and IgA responses against SARS-CoV-2 antigens in 35 patients.
Intranasal influenza vaccine produces strong immune response, Phase I study shows
A Phase I clinical trial has shown that Ad4-H5-VTN, a single-dose, intranasal influenza vaccine, was safe and produced an immune response.
UK launches trial to study alternating COVID-19 vaccines for different doses
The UK Government has given £7 million of funding for a clinical trial which will investigate whether patients can be given different COVID-19 vaccines for each dose.
